| PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. | |
| | |
MedLine Citation:
|
PMID: 20166984 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The resistance of many types of cancer to chemotherapies represents the major hurdle in successful cancer treatment. Cancer cells can escape the toxic effect of most commonly used drugs despite their different chemical structure and intracellular targets. The mechanisms underlying the failure of chemotherapeutic drugs have been well studied. Here I review the role of a signalling pathway activated by the lipid kinase phosphoinositide 3-kinase (PI3K) and the serine/threonine kinase, protein kinase B (PKB) or Akt, in chemotherapeutic resistance. Activation of this pathway plays a key role in different cellular functions such as growth, migration survival and differentiation. Data accumulated in the last decade have established that this pathway plays a key role in cancer development and progression. More recently it has been shown that this pathway plays also a key role in resistance to chemotherapy. Therefore drugs designed to specifically target this pathway are under development to be used as single agent and in combination to chemotherapy to overcome therapeutic resistance. |
| | |
Authors:
|
Marco Falasca |
Related Documents
:
|
19863774 - Synthetic lethality: a framework for the development of wiser cancer therapeutics. 20637264 - Autophagy is a therapeutic target in anticancer drug resistance. 18158134 - Computational methods for analysis of cellular functions and pathways collectively targ... 20045594 - Rna polymerase - an important molecular target of triptolide in cancer cells. 17357204 - Cancer and venous thromboembolism. 2669794 - Gastric cancer: a neoplastic enigma. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current pharmaceutical design Volume: 16 ISSN: 1873-4286 ISO Abbreviation: Curr. Pharm. Des. Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-05-27 Completed Date: 2010-08-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602487 Medline TA: Curr Pharm Des Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1410-6 Citation Subset: IM |
Affiliation:
|
Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, London E1 2AT, UK. m.falasca@qmul.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-Phosphatidylinositol 3-Kinase
/
antagonists & inhibitors* Animals Antineoplastic Combined Chemotherapy Protocols / pharmacology, therapeutic use* Clinical Trials as Topic Drug Resistance, Neoplasm / drug effects* Humans Neoplasms / drug therapy*, enzymology, pathology Protein Kinase Inhibitors / pharmacology, therapeutic use* Proto-Oncogene Proteins c-akt / antagonists & inhibitors* Signal Transduction / drug effects Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Protein Kinase Inhibitors; EC 2.7.1.137/1-Phosphatidylinositol 3-Kinase; EC 2.7.11.1/Proto-Oncogene Proteins c-akt |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cell Cycle as a Target of Antineoplastic Drugs.
Next Document: Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis.